Taylor, K.J., Amdal, C.D., Bjordal, K., Astrup, G.L., Herlofson, B.B., Duprez, F., Gama, R.R., Jacinto, A., Hammerlid, E., Scricciolo, M., Jansen, F., Verdonck-de Leeuw, I.M., Fanetti, G., Guntinas-Lichius, O., Inhestern, J., Dragan, T., Fabian, A., Boehm, A., Wöhner, U., Kiyota, N., Krüger, M., Bonomo, P., Pinto, M., Nuyts, S., Silva, J.C., Stromberger, C., Specenier, P., Tramacere, F., Bushnak, A., Perotti, P., Plath, M., Paderno, A., Stempler, N., Kouri, M., Grégoire, V., Singer, S. 2024. Long-term health-related quality of life in head and neck cancer survivors: A large multinational study. Int J Cancer. 154(10), 1772-1785.
Eichler, M., Distler, U., Nasrullah, U., Krishnan, A., Kaulich, M., Husnjak, K., Eberhardt, W., Rajalingam, K., Tenzer, S., Pfeilschifter, J., Imre, G. 2022. The caspase-2 substrate p54nrb exhibits a multifaceted role in tumor cell death susceptibility via gene regulatory functions. Cell Death Dis. 13(4), 386.
Galle, P.R., Finn, R.S., Qin, S., Ikeda, M., Zhu, A.X., Kim, T.Y., Kudo, M., Breder, V., Merle, P., Kaseb, A., Li, D., Mulla, S., Verret, W., Xu, D.Z., Hernandez, S., Ding, B., Liu, J., Huang, C., Lim, H.Y., Cheng, A.L., Ducreux, M. 2021. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 22(7), 991-1001.